Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 5 Breast Neoplasms 5 Neoplasms 4 Ovarian Neoplasms 3 Neoplasm Metastasis 3 Triple Negative Breast Neoplasms 2 Fallopian Tube Neoplasms 2 Endometrial Neoplasms 2 Colorectal Neoplasms 2 Wilms Tumor 1 Vaginal Neoplasms 1 Uterine Cervical Neoplasms 1 Thrombocythemia, Essential 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Prostatic Diseases 1 Primary Myelofibrosis 1 Premenopausal HR+/HER2- Metastatic Breast Cancer 1 Polycythemia Vera 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Neuroendocrine Tumors 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neuroblastoma 1 Myeloproliferative Disorders 1

Interventions

pembrolizumab 21 enfortumab vedotin 13 Gemcitabine 12 Nivolumab 8 Cisplatin 8 Carboplatin 8 Magnetic Resonance Spectroscopy 6 Specimen Handling 5 Docetaxel 5 toripalimab 4 sacituzumab govitecan 4 Paclitaxel 4 Ipilimumab 4 atezolizumab 3 Mitomycin 3 Fluorouracil 3 disitamab vedotin 2 cabozantinib 2 avelumab 2 Radiosurgery 2 Platinum 2 Injections 2 Immunotherapy 2 Fluorodeoxyglucose F18 2 Cyclophosphamide 2 Biopsy 2 zanidatamab 1 tremelimumab 1 tamibarotene 1 talazoparib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Carcinoma, Transitional Cell × talazoparib × Clear all

NCT04678362 2025-09-22

TALASUR

Centre Francois Baclesse

Phase 2 Recruiting

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡